Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zelluna ASAFRA:7UM0 +1.64%30 Net-Net Working Capital is €0.24 as of Jun. 2026. GuruFocus rates FRA:7UM0 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 843 Biotechnology companies, Zelluna ASA ranks worse than 63.58% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Zelluna ASA's Net-Net Working Capital for the quarter that ended in Jun. 2026 was €0.24.
The industry rank for Zelluna ASA's Net-Net Working Capital or its related term are showing as below:
FRA:7UM0's Price-to-Net-Net-Working-Capital is ranked worse than 63.58% of 843
companies
in the Biotechnology industry
Industry Median: 5.23
vs FRA:7UM0: 7.65
Zelluna ASA (FRA:7UM0) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Zelluna ASA Net-Net Working Capital Related Terms
Zelluna ASA Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Zelluna ASA's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7UM0 vs VRTX, REGN, MRNA: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Zelluna ASA's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelluna ASA Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelluna ASA's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Zelluna ASA's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of €0.24 mean?
Zelluna ASA (FRA:7UM0) has a Net-Net Working Capital of €0.24 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Zelluna ASA According to the industry distribution chart, Zelluna ASA ranks #536 out of 843 companies in the Biotechnology industry, placing it in the top 63.6%.
Is Zelluna ASA's Net-Net Working Capital too high?
Zelluna ASA's current Net-Net Working Capital is €0.24. Based on the distribution chart, Zelluna ASA ranks #536 out of 843 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zelluna ASA has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zelluna ASA ranks #536 out of 843 companies for Net-Net Working Capital. This places Zelluna ASA in the lower half of its industry. The industry median Net-Net Working Capital is 5.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.23, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Zelluna ASA For the Biotechnology industry, the median Net-Net Working Capital is 5.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zelluna ASA's current Net-Net Working Capital is €0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (FRA:7UM0) has a current Net-Net Working Capital of €0.24. The current Net-Net Working Capital is €0.24. Zelluna ASA's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Zelluna ASA (FRA:7UM0), the current Net-Net Working Capital is €0.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
30GF Score
Get the complete analysis for FRA:7UM0
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7UM0 has been successfully added to your 
